Replies to post #15693 on Cytodyn Inc (CYDY)

[BlueHorseshoe13]

Ok, let's clear this up right now.
First, you continue to refer to the lack of 30 patients identified for the trial. You obviously do not understand the very specific parameters placed on identifying those particular patients and why. Please refer to the FDA website and actually read the requirements before you make any more misguided comments on that subject.
Second, you have absolutely NO idea what may or may not be already happening with BP. Using your logic I could just as easily say that a bidding war is currently underway. Neither statement is known to be factual.
Third and finally, at this point you have no idea what the timeline for mono will be, as no one does. There are simply too many variables, many of which will be known in the coming weeks. Enrollment is the important part now. Depending on FDA alone, the timeline could be significantly compressed. Again, we should wait for the facts. In the meantime, you should learn more about the science, and less time pushing your agenda. Best of luck to all.

[BlackDoggie]

I'll agree with you here on one point, and only one point. Mono is the truly disruptive indication in a big picture view. However, your corollary point about adjunct enrollment is nonsensical.

BH covered everything else quite sufficiently.